Thermo Fisher Scientific Inc. (NYSE: TMO) announced the expansion of its bioprocessing capabilities across Asia through new and enlarged facilities in India, South Korea and Singapore.
The company opened a new Bioprocess Design Center in Hyderabad, India, developed in partnership with the Government of Telangana. The facility, located in Genome Valley, provides collaborative spaces for process design, simulation and optimization using single-use and hybrid systems.
Thermo Fisher also expanded existing Bioprocess Design Centers in Incheon, South Korea and Singapore. The Korean facility received enhanced laboratory capabilities and advanced materials, while the Singapore location now offers bench-to-pilot scale bioprocessing and expert-led training programs.
The three centers form a regional network designed to provide local expertise and support for biopharmaceutical companies throughout Asia. The facilities enable customers to develop and test bioprocesses using the company's technologies and receive technical support from Thermo Fisher teams.
"By expanding our network in Korea, Singapore and India, we're bringing world-class infrastructure and expertise closer to our customers, helping them deliver high-quality biologics faster, more cost-effectively and more sustainably," said Daniella Cramp, Senior Vice President and President of BioProduction at Thermo Fisher Scientific.
The expansion supports the growing biopharmaceutical industry in Asia, where demand for biologics, vaccines and cell and gene therapies has increased. Thermo Fisher reported annual revenue of more than $40 billion and provides life sciences research tools, analytical instruments and pharmaceutical services globally.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.